DROXIA 6335 DROXIA 6335 (Droxia 200 mg)
Generic Name: hydroxyurea
Pill imprint DROXIA 6335 DROXIA 6335 has been identified as Droxia 200 mg.
Droxia is used in the treatment of anemia, sickle cell; chronic myelogenous leukemia; solid tumors and belongs to the drug class antimetabolites. There is positive evidence of human fetal risk during pregnancy. Droxia 200 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- hydroxyurea
- Imprint:
- DROXIA 6335 DROXIA 6335
- Strength:
- 200 mg
- Color:
- Green
- Size:
- 16.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Antimetabolites
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Bristol-Myers Squibb
- National Drug Code (NDC):
- 00003-6335
- Inactive Ingredients:
- citric acid monohydrate
gelatin
lactose
magnesium stearate
sodium phosphate
titanium dioxide
FD&C Blue No. 1
FD&C Green No. 3
More about Droxia (hydroxyurea)
Consumer resources
- Other brands: Hydrea
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
